THE UTILITY of the measurement of oestrogen receptor (RE) content of a breast tumour in the management of breast cancer was first proposed by Jensen et al. (1967) . This proposal has since been evaluated by many groups and the measurement of the RE content of human breast carcinomas has been shown to be an important prognostic indicator in early disease (Cooke et al., 1979; Samaan et al., 1981) . Its value in therapeutic policy and predicting response in advanced breast cancer is also well documented (McGuire, 1980; Jensen, 1981) . Various methods have been used to measure the cytoplasmic oestrogen receptor RE, in breast tumours (reviewed by Leake, 1981) . The most commonly used assay is the dextran-coated charcoal (DCC) method, and it has been recommended that any other method be standardized against this procedure (EORTC Breast Co-operative Group, 1980; De Sombre et al., 1979) . However, the DCC assay has certain limitations (Poulsen, 1981) in that it is sensitive to low protein concentrations, high salt concentrations (Peck & Clark, 1977) , and at the elevated temperatures required for "exchange assays" proteolytic degradation becomes significant. The use of hydroxylapatite (HAP) in the assay of RE was first used by Erdos et al. (1970) . The "batch" HAP assay has since been developed and has been reported to overcome all of the drawbacks of the DCC assay (Pavlick & Coulsen, 1976; Garola & McGuire, 1977; Rosner et al., 1980 (Hawkins et al., 1980) . Measurement of the RE,, content of tumours has been reported to improve prediction of response (Laing et al., 1977) . One of the possible reasons for the failure of 400% RE,-positive tumours to respond to endocrine therapy is that there is a defect in the receptor mechanism, distal to the hormone binding to receptor. Such defects have been seen in animal tumour models (Shyamala, 1972) , and failure to translocate hormone-receptor complexes into the nucleus has been observed in human breast tissue (Fazekas & McFarlane, 1980; Thorsen & Stoa, 1979) . It has been proposed that measurement of substantial occupied amounts of RE, by exchange assays would indicate tumours whose translocation mechanism is defective (Thorsen, 1980) . We report here 2 modifications to the HAP assay, 1 to the basic assay, improving the correlation with the standard DCC assay. The other modification counteracts the instability of the unoccupied RE to elevated temperatures, even when bound to HAP. Both modifications serve to increase the accuracy and reproducibility of the assay without increasing the complexity of the procedures used, properties which are of vital importance in the clinical situation.
We have routinely used the single saturating dose DCC assay for the measurement of RE,, and had previously observed a good correlation between this and the number of binding sites determined by Scatchard analysis (e.g. single dose 238-8 fmol receptor/mg protein, Scatchard analysis 245-2 fmol receptor/ mg protein). Tumours were pulverized in liquid N2 and then homogenized in buffer (10 mm Tris/HCl pH 7.4, 1b5 mM EDTA, 0 5 mm monothioglycerol). The homogenate was centrifuged (800 g, 5 min) and the supernatant used as the crude cytosol. The 800 g pellet was washed and then extracted with 0-6M KCI in homogenization buffer for 1 h at 4°C. The crude cytosol and salt extracted pellet were spun at 105,000 g for 30 min at 4°C. The supernatants were used as cytosol and nuclear extract respectively. The DCC assay was performed on cytosol as described by Maynard & Griffiths (1979) except that a single saturating dose was used with or without a 100-fold excess of unlabelled competitor (1 7,Boestradiol) to measure nonspecific binding. The HAP single-point assay was performed by a modification of the method of Thorsen (1979) , such that the HAPreceptor precipitate was collected on GFC filters, on a suction manifold, for radioactive counting, described by Rosner et al. (1980) as a rapid method of collection and washing.
When we compared the RE, content of 20 solid tumours, measured by both DCC and HAP single-point assays, we found a poor correlation between the 2 results (Fig. 1) the REe content of the next 20 tumours, we achieved a much improved linear correlation coefficient of (Fig. 2) . The removal of the interference from nonspecific binding could not be achieved using a buffer wash alone. Under the conditions of the oestradiol wash procedure the labelled oestradiol did not dissociate from the receptor (data not presented).
Similar interference was seen when a Scatchard analysis of the binding data for the assay of total nuclear receptor (REn) measured by HAP exchange assay (21 h at 30°C) was performed. The use of the oestradiol wash procedure with oestradiol (E2) as competitor gave similar results to the measurement of RE,, using diethylstilboestreol (DES) as competitor (DES, Kd=501 x 1010M, nM= 107-2 fmol/mg DNA; E2+ wash, Kd = 5 07 x 10-10M, nM= 123-4 fmol/mg DNA). This modification allows the use of the same molecular species as both ligand and competitor. Results using this modification are comparable with those achieved with DES as competitor, the usual competitor used to eliminate nonspecific and loweraffinity binding (Leake, 1981) .
When we attempted to use the HAP exchange assay to measure occupied cytoplasmic receptor in MCF-7 cells, the results in the Table were obtained, (similar results were seen in human breast tumours). The unoccupied cytoplasmic receptor is unstable at the elevated temperatures necessary for the exchange assay, even when bound to HAP, a procedure which is reported to prevent such degradation (Thorsen, 1980) . This degradation, not previously noticed, meant we could not accurately measure the amount of total cytoplasmic binding (occupied + unoccupied), so the number of occupied sites could not be determined (total-unoccupied). As occupied nuclear receptors are stable to degradation under these conditions (Thorsen, 1979) , we applied this principle to our problem. The cytosol was precharged with radioactive oestradiol, with or without the 100-fold excess of unlabelled competitor, for 3 h at 4°C before binding to HAP, taking care not to dilute the cytosol. The HAP exchange assay was then performed at 30°C for 21 h. As can be seen (Table) the exchange assays can now be performed without degradation occurring. It would appear that, for reasons not yet fully understood, occupation of the hormone binding site on the receptor before HAP precipitation stabilizes the receptor in a way that is not possible after HAP precipitation.
We believe these 2 relatively simple modifications to the HAP receptor assay extend its applicability and increase the accuracy of the measurement of oestrogen receptors in breast tumours.
